inclusion criteria: * age \> 18 years * signed informed consent form * ability to comply with the study protocol in the opinion of the investigator * confirmation of sars-cov2 infection in previous weeks (confirmation of negativity or no activity of sars-cov2 before randomization using the usual tests performed in the hospital), which induced severe pneumonia and ards, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis. * hrct with fibrotic radiological changes of at least 5% after recovery from the acute process (hrct chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge) * be able to understand the information given and sign the informed consent * for women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.

inclusion criteria: * age \> 18 years * signed informed consent form * ability to comply with the study protocol in the opinion of the investigator * confirmation of sars-cov2 infection in previous weeks (confirmation of negativity or no activity of sars-cov2 before randomization using the usual tests performed in the hospital), which induced severe pneumonia and ards, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis. * hrct with fibrotic radiological changes of at least 5% after recovery from the acute process (hrct chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge) * be able to understand the information given and sign the informed consent * for women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.

inclusion criteria: - age > 18 years - signed informed consent form - ability to comply with the study protocol in the opinion of the investigator - confirmation of sars-cov2 infection in previous weeks (confirmation of negativity or no activity of sars-cov2 before randomization using the usual tests performed in the hospital), which induced severe pneumonia and ards, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis. - hrct with fibrotic radiological changes of at least 5% after recovery from the acute process (hrct chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge) - be able to understand the information given and sign the informed consent - for women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.

inclusion criteria: - age > 18 years - signed informed consent form - ability to comply with the study protocol in the opinion of the investigator - confirmation of sars-cov2 infection in previous weeks (confirmation of negativity or no activity of sars-cov2 before randomization using the usual tests performed in the hospital), which induced severe pneumonia and ards, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis. - hrct with fibrotic radiological changes of at least 5% after recovery from the acute process (hrct chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge) - be able to understand the information given and sign the informed consent - for women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.

inclusion criteria: - age > 18 years - signed informed consent form - ability to comply with the study protocol in the opinion of the investigator - confirmation of sars-cov2 infection in previous weeks (with negative pcr at study entry), which induced severe pneumonia and ards, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis. - hrct with fibrotic radiological changes of at least 5% after recovery from the acute process (hrct chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge) - be able to understand the information given and sign the informed consent - for women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.

inclusion criteria: - age > 18 years - signed informed consent form - ability to comply with the study protocol in the opinion of the investigator - confirmation of sars-cov2 infection in previous weeks (with negative pcr at study entry), which induced severe pneumonia and ards, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis. - hrct with fibrotic radiological changes of at least 5% after recovery from the acute process (hrct chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge) - be able to understand the information given and sign the informed consent - for women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.